"uuid:ID","label","rationale","name","instanceType","description","id"
"38b52502-0d24-46e6-afb1-f131955802c7","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","StudyDesign","The main design for the study","StudyDesign_1"
